OncoMatch/Clinical Trials/NCT06772441
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
Is NCT06772441 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Androgen deprivation therapy (ADT) for prostate cancer.
Treatment: Androgen deprivation therapy (ADT) — The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to the National Comprehensive Cancer Network (NCCN) based on multimodal artificial intelligence (MMAI) classification. All patients will receive (i) a dose escalation to the prostate via HDR brachytherapy (boost), (ii) twelve months of ADT and (iii) extremely hypofractionated RT to the prostate (5 fractions). This way, patients in the HypoPro trial will receive a prostate-only dose escalation and benefit from shortening of the ADT compared with current guideline recommendations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT3A (NCCNv4.2023)
Excluded: Stage CN+, CM+
Grade: Grade group 4Grade group 5 (ISUP)
High-risk according to NCCNv4.2023 criteria (cT3a or Grade group 4-5 or PSA > 20 ng/ml); Evidence of pelvic nodal disease (cN+) in mpMRI and/or PSMA-PET/CT; Evidence of distant metastatic disease (cM+) in mpMRI and/or PSMA-PET/CT; Evidence of cT4 disease in mpMRI and/or PSMA-PET/CT
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Prior radiotherapy to the prostate or pelvis
Cannot have received: radical prostatectomy
Prior radical prostatectomy
Cannot have received: focal therapy
Prior focal therapy approaches to the prostate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06772441 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, radical prostatectomy, focal therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT3A is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages